Canis, Martin

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","The Laryngoscope"],["dc.bibliographiccitation.lastpage","9"],["dc.bibliographiccitation.volume","130"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Anczykowski, Mahalia Z."],["dc.contributor.author","Flach, Susanne"],["dc.contributor.author","Spiegel, Jennifer L."],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Jakob, Mark"],["dc.contributor.author","Ihler, Friedrich"],["dc.date.accessioned","2020-01-14T09:01:11Z"],["dc.date.accessioned","2021-10-27T13:22:03Z"],["dc.date.available","2020-01-14T09:01:11Z"],["dc.date.available","2021-10-27T13:22:03Z"],["dc.date.issued","2019"],["dc.description.abstract","OBJECTIVES/HYPOTHESIS: Indication for postoperative radiotherapy in patients with locally circumscribed tumors (pT1-pT2) and a single ipsilateral lymph node metastasis (pN1) is debatable. The aim of this study was to evaluate the oncological long-term outcome of patients with pT1-pT2 pN1 squamous cell carcinoma (SCC) of the oral cavity, the oropharynx, and the hypopharynx without extracapsular spread (ECS) after a margin-negative surgical resection, who either received or did not receive postoperative (chemo)radiotherapy. STUDY DESIGN: Retrospective case series. METHODS: The oncological outcome of patients with pT1-pT2 pN1 SCC without ECS was evaluated retrospectively. All patients underwent primary tumor resection that included transoral laser microsurgery and neck dissection at an academic tertiary referral center. RESULTS: Of 65 identified patients treated between 1986 and 2015 (18 oral cavity, 30 oropharynx, 17 hypopharynx), 21 (32%) received postoperative radiotherapy, and 44 (68%) were treated by surgery alone. The group of patients receiving postoperative treatment showed a significantly superior 5-year disease-specific (94.4% vs. 73.2%, P = .029) and recurrence-free survival (85.2% vs. 43.2%, P = .002), as well as a higher local control rate (90.2% vs. 64.9%, P = .042). The overall survival was 71.4% vs. 62.6% (P = .53). The mean follow-up was 80.7 months. CONCLUSIONS: Patients with locally circumscribed carcinomas and a single ipsilateral ECS-negative lymph node metastasis seem to benefit from postoperative radiotherapy. LEVEL OF EVIDENCE: 4 Laryngoscope, 2019."],["dc.identifier.doi","10.1002/lary.28394"],["dc.identifier.eissn","1531-4995"],["dc.identifier.issn","0023-852X"],["dc.identifier.pmid","31837151"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17078"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92065"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.eissn","1531-4995"],["dc.relation.issn","1531-4995"],["dc.relation.issn","0023-852X"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.subject.ddc","610"],["dc.title","Benefit of postoperative radiotherapy for early tumors with single ipsilateral lymph node metastasis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","33"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Cells"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Jakob, Mark"],["dc.contributor.author","Hambrecht, Mario"],["dc.contributor.author","Spiegel, Jennifer L."],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Dressel, Ralf"],["dc.contributor.author","Streckfuss-Bömeke, Katrin"],["dc.date.accessioned","2021-04-14T08:29:46Z"],["dc.date.available","2021-04-14T08:29:46Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.3390/cells10010033"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17778"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82983"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","MDPI"],["dc.relation.eissn","2073-4409"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Show Comparable Functionality to Their Autologous Origin"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Baumeister, Philipp"],["dc.contributor.author","Hollmann, Alessandra"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Afthonidou, Artemis"],["dc.contributor.author","Simon, Florian"],["dc.contributor.author","Shakhtour, Julius"],["dc.contributor.author","Mack, Brigitte"],["dc.contributor.author","Kranz, Gisela"],["dc.contributor.author","Libl, Darko"],["dc.contributor.author","Leu, Martin"],["dc.contributor.author","Schirmer, Markus A."],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Belka, Claus"],["dc.contributor.author","Zitzelsberger, Horst"],["dc.contributor.author","Ganswindt, Ute"],["dc.contributor.author","Hess, Julia"],["dc.contributor.author","Jakob, Mark"],["dc.contributor.author","Unger, Kristian"],["dc.contributor.author","Gires, Olivier"],["dc.date.accessioned","2020-12-10T18:10:12Z"],["dc.date.available","2020-12-10T18:10:12Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1038/s41598-018-32178-8"],["dc.identifier.eissn","2045-2322"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15447"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/73883"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","High Expression of EpCAM and Sox2 is a Positive Prognosticator of Clinical Outcome for Head and Neck Carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e2006624"],["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","PLoS Biology"],["dc.bibliographiccitation.lastpage","36"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Pan, Min"],["dc.contributor.author","Schinke, Henrik"],["dc.contributor.author","Luxenburger, Elke"],["dc.contributor.author","Kranz, Gisela"],["dc.contributor.author","Shakhtour, Julius"],["dc.contributor.author","Libl, Darko"],["dc.contributor.author","Huang, Yuanchi"],["dc.contributor.author","Gaber, Aljaž"],["dc.contributor.author","Pavšič, Miha"],["dc.contributor.author","Lenarčič, Brigita"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Jakob, Mark"],["dc.contributor.author","Schwenk-Zieger, Sabina"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Hess, Julia"],["dc.contributor.author","Unger, Kristian"],["dc.contributor.author","Baumeister, Philipp"],["dc.contributor.author","Gires, Olivier"],["dc.date.accessioned","2018-11-16T10:48:49Z"],["dc.date.accessioned","2021-10-27T13:21:12Z"],["dc.date.available","2018-11-16T10:48:49Z"],["dc.date.available","2021-10-27T13:21:12Z"],["dc.date.issued","2018"],["dc.description.abstract","Head and neck squamous cell carcinomas (HNSCCs) are characterized by outstanding molecular heterogeneity that results in severe therapy resistance and poor clinical outcome. Inter- and intratumoral heterogeneity in epithelial-mesenchymal transition (EMT) was recently revealed as a major parameter of poor clinical outcome. Here, we addressed the expression and function of the therapeutic target epidermal growth factor receptor (EGFR) and of the major determinant of epithelial differentiation epithelial cell adhesion molecule (EpCAM) in clinical samples and in vitro models of HNSCCs. We describe improved survival of EGFRlow/EpCAMhigh HNSCC patients (n = 180) and provide a molecular basis for the observed disparities in clinical outcome. EGF/EGFR have concentration-dependent dual capacities as inducers of proliferation and EMT through differential activation of the central molecular switch phosphorylated extracellular signal–regulated kinase 1/2 (pERK1/2) and EMT transcription factors (EMT-TFs) Snail, zinc finger E-box-binding homeobox 1 (Zeb1), and Slug. Furthermore, soluble ectodomain of EpCAM (EpEX) was identified as a ligand of EGFR that activates pERK1/2 and phosphorylated AKT (pAKT) and induces EGFR-dependent proliferation but represses EGF-mediated EMT, Snail, Zeb1, and Slug activation and cell migration. EMT repression by EpEX is realized through competitive modulation of pERK1/2 activation strength and inhibition of EMT-TFs, which is reflected in levels of pERK1/2 and its target Slug in clinical samples. Accordingly, high expression of pERK1/2 and/or Slug predicted poor outcome of HNSCCs. Hence, EpEX is a ligand of EGFR that induces proliferation but counteracts EMT mediated by the EGF/EGFR/pERK1/2 axis. Therefore, the emerging EGFR/EpCAM molecular cross talk represents a promising target to improve patient-tailored adjuvant treatment of HNSCCs."],["dc.identifier.doi","10.1371/journal.pbio.2006624"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15666"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92001"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.issn","1545-7885"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","EpCAM ectodomain EpEX is a ligand of EGFR that counteracts EGF-mediated epithelial-mesenchymal transition through modulation of phospho-ERK1/2 in head and neck cancers"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]